ANDA 210763, held by Mylan Labs Ltd. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 210763 (Sodium Nitroprusside), held by Mylan Labs Ltd, was first approved by FDA on Apr 17, 2018, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Sodium nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside injection is also indicated for the treatment of acute congestive heart failure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML · injectable;injection | Sodium Nitroprusside | Rx |
| Jun 11, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 17, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters